Alternative cancer treatments have been growing in acceptance worldwide, positioning HST Global perfectly to launch a wholly owned division focused on opening a new brand of Cancer Treatment Centers. While HST Global continues to look for in-licensing pre-clinical drug candidates, this strategy will allow the company to meet the needs of individuals that face cancer treatments.
Ronald Howell, President and CEO of HST Global, Inc. stated earlier in a press release, “There is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. We have been working with a number of highly visible Physicians that are and have developed successful protocols that are meeting with success in the treatment of this population. As such, we will begin opening a privately branded chain of Cancer Treatment Centers strategically positioned around the world through a new wholly owned subsidiary.”
Mr. Howell continued, “The distribution channel established through our Cancer Treatment Centers will serve as a platform for implementing existing technologies and serve to identify appropriate communities for treatment with new and emerging drug candidates as they become available.”
Cancer is a world epidemic that does not discriminate. HST Global, Inc. has been involved with pre-clinical and proven drug candidates that have demonstrated high efficacy in the treatment of various cancers. The success and high efficacy recognized in these treatments has attracted a number of International partners that want to join the company’s vision and open Centers worldwide. Establishing a global chain of Cancer Treatment Centers will provide an immediate revenue stream to the company.
HST Global believes a number of events will take place in the coming year based on negotiations that have taken place. The Company intends to open its first corporate owned center in the first quarter 2009 and five partner centers worldwide in fiscal 2009. The annual estimated revenue stream from each individual clinic is estimated to be approximately $8-10 million dollars per year.
The Company will continue to search for revolutionary and novel products for the treatment of cancer and other life threatening diseases. Because of the unfortunate nature of cancer, the Company does not believe it will be affected by current or future economic conditions.
Let us hear your thoughts: HST Global, Inc. Message Board